Viewing nowDiovan Film-coated Tablet 80 milligrams (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

MFDS item code 200108763 · Notified 2001.10.16 · Insurance code 653600210
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to effectively control blood pressure in patients with essential hypertension. It is also prescribed for heart failure patients who are intolerant to ACE inhibitors, especially those corresponding to NYHA class II to IV. After myocardial infarction, it helps reduce the risk of death in patients who present with left ventricular dysfunction or impaired systolic function. This drug plays a crucial role in lowering the risk of cardiovascular disease and stabilizing the patient's condition. Therefore, it is used for essential hypertension, heart failure, and reduction of mortality risk after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. If possible, take at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is valsartan 80 mg orally once daily, regardless of sex or race. The antihypertensive effect appears gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. If a diuretic is administered concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg per dose twice daily. Over the following weeks, the dose may be increased according to patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefit of treatment outweighs the risk when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn, especially during pregnancy, so it must be discontinued immediately once pregnancy is confirmed. People who are allergic to this drug or its ingredients, pregnant or nursing women, patients with severe liver impairment or cirrhosis, biliary obstruction patients, hereditary angioedema patients, and patients with severe kidney impairment should not take this drug. Elderly patients, those with elevated potassium levels, patients with liver dysfunction, valvular heart disease, cardiovascular disease, and those with volume depletion need special caution when taking this medication, and careful dose adjustments and observation of condition are important. Possible side effects include dizziness, headache, fatigue, cough, and diarrhea, while rare but serious adverse reactions such as angioedema, kidney impairment, hepatitis, hypoglycemia, and myalgia may occur. Blood pressure may drop sharply, so caution for hypotensive symptoms is necessary when starting the medication or increasing the dosage, especially for patients on dialysis or diuretics. This drug may interact with other antihypertensive medications, diuretics, potassium-sparing diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), and lithium preparations, so consultation with a doctor or pharmacist is essential. Pregnant and nursing women should refrain from using this medication; however, if unavoidable, consultation with a specialist and careful monitoring are required. Safety and efficacy in children or adolescents under 18 years old have not been established, hence its use is not recommended. In case of overdose, symptoms such as hypotension, decreased consciousness, and shock may occur, requiring immediate medical attention for appropriate treatment. This medication should be kept out of reach of children, and transferring it to other containers can lead to accidents or quality degradation, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture exposure and kept in a cool place at a temperature below 30 degrees.
Light red, round film-coated tablet
98 tablets (14 tablets/PTP packaging X 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.